Lithuanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Puslapis 1 nuo 27 rezultatus
Aminoadamantane derivatives as therapeutic agents
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et
Aminoadamantane derivatives as therapeutic agents
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et
Aminoadamantane derivatives as therapeutic agents
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et
Nicotinic attenuation of CNS inflammation and autoimmunity
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND
All publications herein are incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. The following description includes information that may be useful in understanding
Nicotinic attenuation of CNS inflammation and autoimmunity
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND
All publications herein are incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. The following description includes information that may be useful in understanding
Nicotinic attenuation of CNS inflammation and autoimmunity
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND
All publications herein are incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. The following description includes information that may be useful in understanding
Thieno-pyridine derivatives as allosteric enhancers of the GABA.sub.B receptors
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
PRIORITY TO RELATED APPLICATIONS
This application claims the benefit of European Application No. 04106665.5, filed Dec. 17, 2004, which is hereby incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
.gamma.-Aminobutyric acid (GABA), the most abundant inhibitory neurotransmitter,
Phenyl-substituted nicotinic ligands, and methods of use thereof
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND OF THE INVENTION
Neuronal nicotinic acetylcholine receptors (nAChRs) serve a wide range of physiological functions and have been implicated in a number of pathological processes and pharmacological effects of nicotinic drugs. Many of the important in vivo effects of nicotine in the
Phenyl-substituted nicotinic ligands, and methods of use thereof
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND OF THE INVENTION
Neuronal nicotinic acetylcholine receptors (nAChRs) serve a wide range of physiological functions and have been implicated in a number of pathological processes and pharmacological effects of nicotinic drugs. Many of the important in vivo effects of nicotine in the
Urea compounds and their use as enzyme inhibitors
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
FIELD OF THE INVENTION
The present invention relates to compounds and their uses, and in particular to compounds and their therapeutic use in the treatment or prevention of conditions having an association with substrates, such as the neurotransmitter anandamide, which are broken down by the fatty
Urea compounds and their use as enzyme inhibitors
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
FIELD OF THE INVENTION
The present invention relates to compounds and their uses, and in particular to compounds and their therapeutic use in the treatment or prevention of conditions having an association with substrates, such as the neurotransmitter anandamide, which are broken down by the fatty
Triazinedione derivatives as GABA.sub.B receptor modulators
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
SUMMARY OF THE INVENTION
##STR00002##
The present invention provides novel compounds of formula I wherein W.sub.1, W.sub.2, W.sub.3, W.sub.4, W.sub.5, B, X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5, E and L are as defined herein; invention compounds are gamma amino butyric acid receptor-subtype B
Triazinedione derivatives as GABA.sub.B receptor modulators
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
SUMMARY OF THE INVENTION
##STR00002##
The present invention provides novel compounds of formula I wherein W.sub.1, W.sub.2, W.sub.3, W.sub.4, W.sub.5, B, X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5, E and L are as defined herein; invention compounds are gamma amino butyric acid receptor-subtype B
6H-oxazolo[4,5 e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
The invention relates to 6H-oxazolo[4,5-e]indole derivatives of the formula I
##STR00002## in which R.sup.1 is H or Het.sup.1, R.sup.2 is H, A, cycloalkyl, --(CH.sub.2).sub.p--N(R.sup.5).sub.2, --(CH.sub.2).sub.p--OR.sup.5, --(CH.sub.2).sub.n--Ar or --(CH.sub.2).sub.n-Het, R.sup.3 is H, Hal, OH, OA
6H-oxazolo[4,5-e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
The invention relates to 6H-oxazolo[4,5-e]indole derivatives of the formula I
##STR00002## in which
R.sup.1 is H or Het.sup.1,
R.sup.2 is H, A, cycloalkyl, --(CH.sub.2).sub.p--N(R.sup.5).sub.2, --(CH.sub.2).sub.p--OR.sup.5, --(CH.sub.2).sub.n--Ar or --(CH.sub.2).sub.n-Het,
R.sup.3 is H, Hal, OH, OA
Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu
- Dirba 55 kalbomis
- Žolelių gydymas, paremtas mokslu
- Vaistažolių atpažinimas pagal vaizdą
- Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
- Skaitykite mokslines publikacijas, susijusias su jūsų paieška
- Ieškokite vaistinių žolelių pagal jų poveikį
- Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus
Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais
